Authors
Loading...
Preclinical evaluation shows ARV-6723 improves antitumor activity in ICI-resistant tumor models, suggesting its promise as a treatment option.
Acker et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: